Reviewed by Christian Espinosa, MBA, CISSP · Founder & CEO
Published May 2025 · Last reviewed May 2026
The Med Device Cyber Podcast · May 1, 2025 This podcast episode delves into the potential shifts in medical device cybersecurity guidelines and FDA regulations under new administrations, specifically examining the impacts of a possible Trump and RFK Jr. influence. The hosts discuss the anticipated push for efficiency within the FDA, which might lead to a reduction in bureaucratic processes but could also introduce new complexities for regulatory approvals. A key concern highlighted is the potential for increased challenges for small and startup medical device manufacturers due to tighter regulations and longer approval timelines, contrasting with the greater runway available to larger, established companies. The conversation also explores the implications of potential tariffs on Chinese components, increased scrutiny of the medical device supply chain, and the future of semiconductor manufacturing in the US. The hosts touch upon the controversial idea of abolishing or restructuring the FDA into separate entities for food, drugs, and medical devices. This episode offers valuable insights for product security teams, regulatory leads, and engineers looking to understand and prepare for upcoming changes in the MedTech cybersecurity landscape. It emphasizes the importance of proactive regulatory planning and the "early and often" approach for manufacturers to navigate these evolving challenges effectively.
Key Takeaways
- The Trump administration's focus on efficiency could streamline some FDA processes, but also create new regulatory complexities for medical device approvals.
- Small and startup medical device manufacturers may face significant delays and increased costs due to potential stricter regulations and tariffs, unlike larger, more established companies.
- Proposed tariffs on Chinese components and increased scrutiny of the supply chain will likely raise the cost of innovation and device acquisition.
- The effectiveness of government entities like the FDA and TSA is often debated, with discussions around privatizing certain functions and the need for greater transparency.
- Manufacturers should prioritize proactive regulatory planning and adopt an 'early and often' development approach to navigate evolving cybersecurity guidelines and potential FDA delays.
- Considering the potential for changes in FDA leadership and structure, medical device companies must remain agile and adaptable to new regulatory environments.
Listen on mdcpodcast.com · Watch on YouTube
Listen to this episode
Want help applying this to your own device program?
Blue Goat Cyber is a specialist medical device cybersecurity firm: 250+ FDA submissions, zero rejections. If anything in this conversation hit close to home, book a 30-minute strategy session - no cost, no obligation.